Association of Anti-tuberculosis Drug Concentrations in Hair and Treatment Outcomes in MDR- and XDR-TB

Overview

Journal ERJ Open Res

Specialty Pulmonary Medicine

Date 2019 May 2

PMID 31041318

Citations 8

Authors

John Metcalfe

Peter Bacchetti

Roy Gerona

Ali Esmail

Keertan Dheda

Monica Gandhi

Affiliations

Soon will be listed here.

Abstract

Therapeutic drug monitoring for drug-resistant tuberculosis (TB) is likely to improve treatment outcomes. While assessments of plasma drug levels can explain pharmacokinetic variability among trial participants, these measures require phlebotomy and a cold chain, and are generally not repeated frequently enough to characterise drug exposure over time. Using a novel multi-analyte assay, we found evidence that higher anti-TB drug concentrations in hair, a non-biohazardous and noninvasively collected biomatrix, predict extensively-drug resistant-TB clinical outcomes in a high-burden setting.

Citing Articles

Isoniazid hair drug levels among TB patients as a tool to monitor adherence, exposure, and TB treatment outcomes and its acceptability in a multicultural setting. A narrative review.

Muzanyi G, Ntale M, Salata R, Joloba M, Mukonzo J, Mafigiri D Afr Health Sci. 2024; 23(4):28-34.

PMID: 38974301 PMC: 11225455. DOI: 10.4314/ahs.v23i4.5.

Preferred techniques of hair harvest for medical testing among adult pulmonary TB patients.

Muzanyi G, Mafigiri D, Salata R, Joloba M, Mukonzo J, Ntale M Afr Health Sci. 2024; 23(4):35-41.

PMID: 38974289 PMC: 11225486. DOI: 10.4314/ahs.v23i4.6.

Push forward LC-MS-based therapeutic drug monitoring and pharmacometabolomics for anti-tuberculosis precision dosing and comprehensive clinical management.

Thu N, Tien N, Yen N, Duong T, Long N, Nguyen H J Pharm Anal. 2024; 14(1):16-38.

PMID: 38352944 PMC: 10859566. DOI: 10.1016/j.jpha.2023.09.009.

Therapeutic drug monitoring of corticosteroids/β-agonists in the hair of patients with asthma: an open-label feasibility study.

Salvator H, Lamy E, Roquencourt C, Bardin E, Devillier P, Grassin-Delyle S Front Pharmacol. 2024; 14:1339835.

PMID: 38269282 PMC: 10807032. DOI: 10.3389/fphar.2023.1339835.

Measurement Tools and Utility of Hair Analysis for Screening Adherence to Antihypertensive Medication.

Sharma J, Dludla P, Dwivedi G, Johnson R Glob Heart. 2023; 18(1):17.

PMID: 36968302 PMC: 10038111. DOI: 10.5334/gh.1191.

References

Vernon A, Burman W, Benator D, Khan A, Bozeman L . Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet. 1999; 353(9167):1843-7. DOI: 10.1016/s0140-6736(98)11467-8. View

Benator D, Bhattacharya M, Bozeman L, Burman W, Cantazaro A, Chaisson R . Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet. 2002; 360(9332):528-34. DOI: 10.1016/s0140-6736(02)09742-8. View

Weiner M, Burman W, Vernon A, Benator D, Peloquin C, Khan A . Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med. 2003; 167(10):1341-7. DOI: 10.1164/rccm.200208-951OC. View

Gurumurthy P, Ramachandran G, Hemanth Kumar A, Rajasekaran S, Padmapriyadarsini C, Swaminathan S . Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. Antimicrob Agents Chemother. 2004; 48(11):4473-5. PMC: 525439. DOI: 10.1128/AAC.48.11.4473-4475.2004. View

Weiner M, Benator D, Burman W, Peloquin C, Khan A, Vernon A . Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis. 2005; 40(10):1481-91. DOI: 10.1086/429321. View

Burman W, Benator D, Vernon A, Khan A, Jones B, Silva C . Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med. 2005; 173(3):350-6. DOI: 10.1164/rccm.200503-417OC. View

Holland D, Hamilton C, Weintrob A, Engemann J, Fortenberry E, Peloquin C . Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection. Pharmacotherapy. 2009; 29(5):503-10. DOI: 10.1592/phco.29.5.503. View

Chideya S, Winston C, Peloquin C, Bradford W, Hopewell P, Wells C . Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis. 2009; 48(12):1685-94. PMC: 3762461. DOI: 10.1086/599040. View

Barroso E, Pinheiro V, Facanha M, Carvalho M, Moura M, Campelo C . Serum concentrations of rifampin, isoniazid, and intestinal absorption, permeability in patients with multidrug resistant tuberculosis. Am J Trop Med Hyg. 2009; 81(2):322-9. View

10.

Ankomah P, Levin B . Two-drug antimicrobial chemotherapy: a mathematical model and experiments with Mycobacterium marinum. PLoS Pathog. 2012; 8(1):e1002487. PMC: 3257304. DOI: 10.1371/journal.ppat.1002487. View

11.

McIlleron H, Rustomjee R, Vahedi M, Mthiyane T, Denti P, Connolly C . Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines. Antimicrob Agents Chemother. 2012; 56(6):3232-8. PMC: 3370773. DOI: 10.1128/AAC.05526-11. View

12.

Van Tongeren L, Nolan S, Cook V, Fitzgerald J, Johnston J . Therapeutic drug monitoring in the treatment of tuberculosis: a retrospective analysis. Int J Tuberc Lung Dis. 2013; 17(2):221-4. DOI: 10.5588/ijtld.12.0279. View

13.

Ford C, Shah R, Maeda M, Gagneux S, Murray M, Cohen T . Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug-resistant tuberculosis. Nat Genet. 2013; 45(7):784-90. PMC: 3777616. DOI: 10.1038/ng.2656. View

14.

Pasipanodya J, McIlleron H, Burger A, Wash P, Smith P, Gumbo T . Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis. 2013; 208(9):1464-73. PMC: 3789573. DOI: 10.1093/infdis/jit352. View

15.

Gandhi M, Yang Q, Bacchetti P, Huang Y . Short communication: A low-cost method for analyzing nevirapine levels in hair as a marker of adherence in resource-limited settings. AIDS Res Hum Retroviruses. 2013; 30(1):25-8. PMC: 3887402. DOI: 10.1089/aid.2013.0239. View

16.

Mpagama S, Ndusilo N, Stroup S, Kumburu H, Peloquin C, Gratz J . Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2013; 58(2):782-8. PMC: 3910816. DOI: 10.1128/AAC.01549-13. View

17.

Liu A, Yang Q, Huang Y, Bacchetti P, Anderson P, Jin C . Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP). PLoS One. 2014; 9(1):e83736. PMC: 3885443. DOI: 10.1371/journal.pone.0083736. View

18.

Daftary A, Padayatchi N, ODonnell M . Preferential adherence to antiretroviral therapy over tuberculosis treatment: a qualitative study of drug-resistant TB/HIV co-infected patients in South Africa. Glob Public Health. 2014; 9(9):1107-16. PMC: 4198425. DOI: 10.1080/17441692.2014.934266. View

19.

Prahl J, Johansen I, Cohen A, Frimodt-Moller N, Andersen A . Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study--authors' response. J Antimicrob Chemother. 2014; 70(1):321-2. DOI: 10.1093/jac/dku373. View

20.

Baciu T, Borrull F, Aguilar C, Calull M . Recent trends in analytical methods and separation techniques for drugs of abuse in hair. Anal Chim Acta. 2014; 856:1-26. DOI: 10.1016/j.aca.2014.06.051. View